Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: Depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-αGal antibody

Ian P J Alwayn, Yuanxin Xu, Murali Basker, Cecelia Wu, Leo Buhler, Denis Lambrigts, Sarah Treter, David Harper, Hiroshi Kitamura, Ellen S. Vitetta, Sonny Abraham, Michel Awwad, Mary E. White-Scharf, David H. Sachs, Aron Thall, David K C Cooper

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Anti-Galαl-3Gal antibodies (antiαGal Ab) are a major barrier to clinical xenotransplantation as they are believed to initiate both hyperacute and acute humoral rejection. Extracorporeal immunoadsorption (EIA) with αGal oligosaccharide columns temporarily depletes antiαGal Ab, but their return is ultimately associated with graft destruction. We therefore assessed the ability of two immunotoxins (IT) and two monoclonal antibodies (mAb) to deplete B and/or plasma cells both in vitro and in vivo in baboons, and to observe the rate of return of antiαGal Ab following EIA. The effects of the mouse anti-human IT anti-CD22-ricin A (∝CD22-IT, directed against a B cell determinant) and anti-CD38-ricin A (∝CD38-IT, B and plasma cell determinant) and the mouse anti-human anti-CD38 mAb (∝CD38 mAb) and mouse/human chimeric anti-human anti-CD20 mAb (∝CD20 mAb, Rituximab, B cell determinant) on B and plasma cell depletion and antiαGal Ab production were assessed both in vitro and in vivo in baboons (n=9) that had previously undergone splenectomy. For comparison, two baboons received nonmyeloablative whole body irradiation (WBI) (300 cGy), and one received myeloablative WBI (900 cGy). Depletion of B cells was monitored by flow cytometry of blood, bone marrow (BM) and lymph nodes (LN), staining with anti-CD20 and/or anti-CD22 mAbs, and by histology of LN. EIA was carried out after the therapy and antiαGal Ab levels were measured daily. In vitro ∝CD22-IT inhibited protein synthesis in the human Daudi B cell line more effectively than ∝CD38-IT. Upon differentiation of B cells into plasma cells, however, less inhibition of protein synthesis after ∝CD22-IT treatment was observed. Depleting CD20-positive cells in vitro from a baboon spleen cell population already depleted of granulocytes, monocytes, and T cells led to a relative enrichment of CD20-negative cells, that is plasma cells, and consequently resulted in a significant increase in antiαGal Ab production by the remaining cells, whereas depleting CD38-positive cells resulted in a significant decrease in antiαGal Ab production. In vivo, WBI (300 or 900 cGy) resulted in 100% B cell depletion in blood and BM, >80% depletion in LN, with substantial recovery of B cells after 21 days and only transient reduction in antiαGal Ab after EIA. ∝CD22-IT depleted B cells by >97% in blood and BM. and by 60% in LN, but a rebound of B cells was observed after 14 and 62 days in LN and blood, respectively. At 7 days, serum antiαGal IgG and IgM Ab levels were reduced by a maximum of 40-45% followed by a rebound to levels up to 12-fold that of baseline antiαGal Ab by day 83 in one baboon. The results obtained with ∝CD38-IT were inconclusive. This may have been, in part, due to inadequate conjugation of the toxin. Cell coating was 100% with ∝CD38 mAb, but no changes in antiαGal Ab production were observed. ∝CD20 mAb resulted in 100% depletion orb cells in blood and BM, and 80% in LN, with recovery orb cells starting at day 42. Adding 150cGy WBI at this time led to 100% depletion of B cells in the BM and LN. Although B cell depletion in blood and BM persisted for>3 months, the reduction of serum antiαGal IgG or IgM Ab levels was not sustained beyond 2 days. ∝CD20 mAb+WBI totally and efficiently depleted CD20- and CD22-positive B cells in blood, BM, and LN for>3 months in vivo, but there was no sustained clinically significant reduction in serum antiαGal Ab. The majority of antibody secretors are CD38-positive cells, but targeting these cells in vitro or in vivo with ∝CD38-IT was not very effective. These observations suggest that CD20-and CD22-positive B cells are not the major source of antiαGal Ab production. Future efforts will be directed towards suppression of plasma cell function.

Original languageEnglish (US)
Pages (from-to)157-171
Number of pages15
JournalXenotransplantation
Volume8
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Papio
Plasma Cells
Immunotherapy
Antibody Formation
Anti-Idiotypic Antibodies
Immunotoxins
B-Lymphocytes
Lymph Nodes
Monoclonal Antibodies
Whole-Body Irradiation
Bone Marrow
Antibodies
Ricin
Immunoglobulin M
Immunoglobulin G
Serum
Heterologous Transplantation
Splenectomy
Oligosaccharides
Granulocytes

Keywords

  • Anti-αGal antibodies
  • Anti-CD20 monoclonal antibody
  • Anti-CD22-ricin A immunotoxin
  • Anti-CD38-ricin A immunotoxin
  • B cells
  • Plasma cells
  • Primates
  • Xenotransplantation

ASJC Scopus subject areas

  • Immunology

Cite this

Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons : Depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-αGal antibody. / Alwayn, Ian P J; Xu, Yuanxin; Basker, Murali; Wu, Cecelia; Buhler, Leo; Lambrigts, Denis; Treter, Sarah; Harper, David; Kitamura, Hiroshi; Vitetta, Ellen S.; Abraham, Sonny; Awwad, Michel; White-Scharf, Mary E.; Sachs, David H.; Thall, Aron; Cooper, David K C.

In: Xenotransplantation, Vol. 8, No. 3, 2001, p. 157-171.

Research output: Contribution to journalArticle

Alwayn, IPJ, Xu, Y, Basker, M, Wu, C, Buhler, L, Lambrigts, D, Treter, S, Harper, D, Kitamura, H, Vitetta, ES, Abraham, S, Awwad, M, White-Scharf, ME, Sachs, DH, Thall, A & Cooper, DKC 2001, 'Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: Depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-αGal antibody', Xenotransplantation, vol. 8, no. 3, pp. 157-171. https://doi.org/10.1034/j.1399-3089.2001.008003157.x
Alwayn, Ian P J ; Xu, Yuanxin ; Basker, Murali ; Wu, Cecelia ; Buhler, Leo ; Lambrigts, Denis ; Treter, Sarah ; Harper, David ; Kitamura, Hiroshi ; Vitetta, Ellen S. ; Abraham, Sonny ; Awwad, Michel ; White-Scharf, Mary E. ; Sachs, David H. ; Thall, Aron ; Cooper, David K C. / Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons : Depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-αGal antibody. In: Xenotransplantation. 2001 ; Vol. 8, No. 3. pp. 157-171.
@article{d5ce01e97faf45c588fc69c437a3c6bc,
title = "Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: Depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-αGal antibody",
abstract = "Anti-Galαl-3Gal antibodies (antiαGal Ab) are a major barrier to clinical xenotransplantation as they are believed to initiate both hyperacute and acute humoral rejection. Extracorporeal immunoadsorption (EIA) with αGal oligosaccharide columns temporarily depletes antiαGal Ab, but their return is ultimately associated with graft destruction. We therefore assessed the ability of two immunotoxins (IT) and two monoclonal antibodies (mAb) to deplete B and/or plasma cells both in vitro and in vivo in baboons, and to observe the rate of return of antiαGal Ab following EIA. The effects of the mouse anti-human IT anti-CD22-ricin A (∝CD22-IT, directed against a B cell determinant) and anti-CD38-ricin A (∝CD38-IT, B and plasma cell determinant) and the mouse anti-human anti-CD38 mAb (∝CD38 mAb) and mouse/human chimeric anti-human anti-CD20 mAb (∝CD20 mAb, Rituximab, B cell determinant) on B and plasma cell depletion and antiαGal Ab production were assessed both in vitro and in vivo in baboons (n=9) that had previously undergone splenectomy. For comparison, two baboons received nonmyeloablative whole body irradiation (WBI) (300 cGy), and one received myeloablative WBI (900 cGy). Depletion of B cells was monitored by flow cytometry of blood, bone marrow (BM) and lymph nodes (LN), staining with anti-CD20 and/or anti-CD22 mAbs, and by histology of LN. EIA was carried out after the therapy and antiαGal Ab levels were measured daily. In vitro ∝CD22-IT inhibited protein synthesis in the human Daudi B cell line more effectively than ∝CD38-IT. Upon differentiation of B cells into plasma cells, however, less inhibition of protein synthesis after ∝CD22-IT treatment was observed. Depleting CD20-positive cells in vitro from a baboon spleen cell population already depleted of granulocytes, monocytes, and T cells led to a relative enrichment of CD20-negative cells, that is plasma cells, and consequently resulted in a significant increase in antiαGal Ab production by the remaining cells, whereas depleting CD38-positive cells resulted in a significant decrease in antiαGal Ab production. In vivo, WBI (300 or 900 cGy) resulted in 100{\%} B cell depletion in blood and BM, >80{\%} depletion in LN, with substantial recovery of B cells after 21 days and only transient reduction in antiαGal Ab after EIA. ∝CD22-IT depleted B cells by >97{\%} in blood and BM. and by 60{\%} in LN, but a rebound of B cells was observed after 14 and 62 days in LN and blood, respectively. At 7 days, serum antiαGal IgG and IgM Ab levels were reduced by a maximum of 40-45{\%} followed by a rebound to levels up to 12-fold that of baseline antiαGal Ab by day 83 in one baboon. The results obtained with ∝CD38-IT were inconclusive. This may have been, in part, due to inadequate conjugation of the toxin. Cell coating was 100{\%} with ∝CD38 mAb, but no changes in antiαGal Ab production were observed. ∝CD20 mAb resulted in 100{\%} depletion orb cells in blood and BM, and 80{\%} in LN, with recovery orb cells starting at day 42. Adding 150cGy WBI at this time led to 100{\%} depletion of B cells in the BM and LN. Although B cell depletion in blood and BM persisted for>3 months, the reduction of serum antiαGal IgG or IgM Ab levels was not sustained beyond 2 days. ∝CD20 mAb+WBI totally and efficiently depleted CD20- and CD22-positive B cells in blood, BM, and LN for>3 months in vivo, but there was no sustained clinically significant reduction in serum antiαGal Ab. The majority of antibody secretors are CD38-positive cells, but targeting these cells in vitro or in vivo with ∝CD38-IT was not very effective. These observations suggest that CD20-and CD22-positive B cells are not the major source of antiαGal Ab production. Future efforts will be directed towards suppression of plasma cell function.",
keywords = "Anti-αGal antibodies, Anti-CD20 monoclonal antibody, Anti-CD22-ricin A immunotoxin, Anti-CD38-ricin A immunotoxin, B cells, Plasma cells, Primates, Xenotransplantation",
author = "Alwayn, {Ian P J} and Yuanxin Xu and Murali Basker and Cecelia Wu and Leo Buhler and Denis Lambrigts and Sarah Treter and David Harper and Hiroshi Kitamura and Vitetta, {Ellen S.} and Sonny Abraham and Michel Awwad and White-Scharf, {Mary E.} and Sachs, {David H.} and Aron Thall and Cooper, {David K C}",
year = "2001",
doi = "10.1034/j.1399-3089.2001.008003157.x",
language = "English (US)",
volume = "8",
pages = "157--171",
journal = "Xenotransplantation",
issn = "0908-665X",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons

T2 - Depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-αGal antibody

AU - Alwayn, Ian P J

AU - Xu, Yuanxin

AU - Basker, Murali

AU - Wu, Cecelia

AU - Buhler, Leo

AU - Lambrigts, Denis

AU - Treter, Sarah

AU - Harper, David

AU - Kitamura, Hiroshi

AU - Vitetta, Ellen S.

AU - Abraham, Sonny

AU - Awwad, Michel

AU - White-Scharf, Mary E.

AU - Sachs, David H.

AU - Thall, Aron

AU - Cooper, David K C

PY - 2001

Y1 - 2001

N2 - Anti-Galαl-3Gal antibodies (antiαGal Ab) are a major barrier to clinical xenotransplantation as they are believed to initiate both hyperacute and acute humoral rejection. Extracorporeal immunoadsorption (EIA) with αGal oligosaccharide columns temporarily depletes antiαGal Ab, but their return is ultimately associated with graft destruction. We therefore assessed the ability of two immunotoxins (IT) and two monoclonal antibodies (mAb) to deplete B and/or plasma cells both in vitro and in vivo in baboons, and to observe the rate of return of antiαGal Ab following EIA. The effects of the mouse anti-human IT anti-CD22-ricin A (∝CD22-IT, directed against a B cell determinant) and anti-CD38-ricin A (∝CD38-IT, B and plasma cell determinant) and the mouse anti-human anti-CD38 mAb (∝CD38 mAb) and mouse/human chimeric anti-human anti-CD20 mAb (∝CD20 mAb, Rituximab, B cell determinant) on B and plasma cell depletion and antiαGal Ab production were assessed both in vitro and in vivo in baboons (n=9) that had previously undergone splenectomy. For comparison, two baboons received nonmyeloablative whole body irradiation (WBI) (300 cGy), and one received myeloablative WBI (900 cGy). Depletion of B cells was monitored by flow cytometry of blood, bone marrow (BM) and lymph nodes (LN), staining with anti-CD20 and/or anti-CD22 mAbs, and by histology of LN. EIA was carried out after the therapy and antiαGal Ab levels were measured daily. In vitro ∝CD22-IT inhibited protein synthesis in the human Daudi B cell line more effectively than ∝CD38-IT. Upon differentiation of B cells into plasma cells, however, less inhibition of protein synthesis after ∝CD22-IT treatment was observed. Depleting CD20-positive cells in vitro from a baboon spleen cell population already depleted of granulocytes, monocytes, and T cells led to a relative enrichment of CD20-negative cells, that is plasma cells, and consequently resulted in a significant increase in antiαGal Ab production by the remaining cells, whereas depleting CD38-positive cells resulted in a significant decrease in antiαGal Ab production. In vivo, WBI (300 or 900 cGy) resulted in 100% B cell depletion in blood and BM, >80% depletion in LN, with substantial recovery of B cells after 21 days and only transient reduction in antiαGal Ab after EIA. ∝CD22-IT depleted B cells by >97% in blood and BM. and by 60% in LN, but a rebound of B cells was observed after 14 and 62 days in LN and blood, respectively. At 7 days, serum antiαGal IgG and IgM Ab levels were reduced by a maximum of 40-45% followed by a rebound to levels up to 12-fold that of baseline antiαGal Ab by day 83 in one baboon. The results obtained with ∝CD38-IT were inconclusive. This may have been, in part, due to inadequate conjugation of the toxin. Cell coating was 100% with ∝CD38 mAb, but no changes in antiαGal Ab production were observed. ∝CD20 mAb resulted in 100% depletion orb cells in blood and BM, and 80% in LN, with recovery orb cells starting at day 42. Adding 150cGy WBI at this time led to 100% depletion of B cells in the BM and LN. Although B cell depletion in blood and BM persisted for>3 months, the reduction of serum antiαGal IgG or IgM Ab levels was not sustained beyond 2 days. ∝CD20 mAb+WBI totally and efficiently depleted CD20- and CD22-positive B cells in blood, BM, and LN for>3 months in vivo, but there was no sustained clinically significant reduction in serum antiαGal Ab. The majority of antibody secretors are CD38-positive cells, but targeting these cells in vitro or in vivo with ∝CD38-IT was not very effective. These observations suggest that CD20-and CD22-positive B cells are not the major source of antiαGal Ab production. Future efforts will be directed towards suppression of plasma cell function.

AB - Anti-Galαl-3Gal antibodies (antiαGal Ab) are a major barrier to clinical xenotransplantation as they are believed to initiate both hyperacute and acute humoral rejection. Extracorporeal immunoadsorption (EIA) with αGal oligosaccharide columns temporarily depletes antiαGal Ab, but their return is ultimately associated with graft destruction. We therefore assessed the ability of two immunotoxins (IT) and two monoclonal antibodies (mAb) to deplete B and/or plasma cells both in vitro and in vivo in baboons, and to observe the rate of return of antiαGal Ab following EIA. The effects of the mouse anti-human IT anti-CD22-ricin A (∝CD22-IT, directed against a B cell determinant) and anti-CD38-ricin A (∝CD38-IT, B and plasma cell determinant) and the mouse anti-human anti-CD38 mAb (∝CD38 mAb) and mouse/human chimeric anti-human anti-CD20 mAb (∝CD20 mAb, Rituximab, B cell determinant) on B and plasma cell depletion and antiαGal Ab production were assessed both in vitro and in vivo in baboons (n=9) that had previously undergone splenectomy. For comparison, two baboons received nonmyeloablative whole body irradiation (WBI) (300 cGy), and one received myeloablative WBI (900 cGy). Depletion of B cells was monitored by flow cytometry of blood, bone marrow (BM) and lymph nodes (LN), staining with anti-CD20 and/or anti-CD22 mAbs, and by histology of LN. EIA was carried out after the therapy and antiαGal Ab levels were measured daily. In vitro ∝CD22-IT inhibited protein synthesis in the human Daudi B cell line more effectively than ∝CD38-IT. Upon differentiation of B cells into plasma cells, however, less inhibition of protein synthesis after ∝CD22-IT treatment was observed. Depleting CD20-positive cells in vitro from a baboon spleen cell population already depleted of granulocytes, monocytes, and T cells led to a relative enrichment of CD20-negative cells, that is plasma cells, and consequently resulted in a significant increase in antiαGal Ab production by the remaining cells, whereas depleting CD38-positive cells resulted in a significant decrease in antiαGal Ab production. In vivo, WBI (300 or 900 cGy) resulted in 100% B cell depletion in blood and BM, >80% depletion in LN, with substantial recovery of B cells after 21 days and only transient reduction in antiαGal Ab after EIA. ∝CD22-IT depleted B cells by >97% in blood and BM. and by 60% in LN, but a rebound of B cells was observed after 14 and 62 days in LN and blood, respectively. At 7 days, serum antiαGal IgG and IgM Ab levels were reduced by a maximum of 40-45% followed by a rebound to levels up to 12-fold that of baseline antiαGal Ab by day 83 in one baboon. The results obtained with ∝CD38-IT were inconclusive. This may have been, in part, due to inadequate conjugation of the toxin. Cell coating was 100% with ∝CD38 mAb, but no changes in antiαGal Ab production were observed. ∝CD20 mAb resulted in 100% depletion orb cells in blood and BM, and 80% in LN, with recovery orb cells starting at day 42. Adding 150cGy WBI at this time led to 100% depletion of B cells in the BM and LN. Although B cell depletion in blood and BM persisted for>3 months, the reduction of serum antiαGal IgG or IgM Ab levels was not sustained beyond 2 days. ∝CD20 mAb+WBI totally and efficiently depleted CD20- and CD22-positive B cells in blood, BM, and LN for>3 months in vivo, but there was no sustained clinically significant reduction in serum antiαGal Ab. The majority of antibody secretors are CD38-positive cells, but targeting these cells in vitro or in vivo with ∝CD38-IT was not very effective. These observations suggest that CD20-and CD22-positive B cells are not the major source of antiαGal Ab production. Future efforts will be directed towards suppression of plasma cell function.

KW - Anti-αGal antibodies

KW - Anti-CD20 monoclonal antibody

KW - Anti-CD22-ricin A immunotoxin

KW - Anti-CD38-ricin A immunotoxin

KW - B cells

KW - Plasma cells

KW - Primates

KW - Xenotransplantation

UR - http://www.scopus.com/inward/record.url?scp=17844402696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844402696&partnerID=8YFLogxK

U2 - 10.1034/j.1399-3089.2001.008003157.x

DO - 10.1034/j.1399-3089.2001.008003157.x

M3 - Article

C2 - 11472623

AN - SCOPUS:17844402696

VL - 8

SP - 157

EP - 171

JO - Xenotransplantation

JF - Xenotransplantation

SN - 0908-665X

IS - 3

ER -